Daejeon, South Korea

Seung Dal Seo

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Jskbiomed Inc.. Active years: 2022.


% Patents Active = 100.0

 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Seung Dal Seo: Innovator in Microjet Drug Injection Technology

Introduction

Seung Dal Seo is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of medical technology, particularly in drug delivery systems. His innovative approach has led to the development of a unique device that enhances the efficiency of drug administration.

Latest Patents

One of Seung Dal Seo's notable inventions is a microjet drug injection device equipped with a backflow prevention valve. This device is designed to ensure that the drug moves only towards the injection nozzle, preventing any backflow. The invention comprises an upper housing, a lower housing, a partition, and a specialized backflow prevention valve with a slit for drug passage. This innovation is crucial for improving the safety and effectiveness of drug injections.

Career Highlights

Seung Dal Seo is currently associated with Jskbiomed Inc., where he continues to work on advancing medical technologies. His dedication to innovation has earned him recognition in the field, and he is known for his meticulous approach to research and development.

Collaborations

Seung Dal Seo collaborates with talented individuals such as Jin Woo Jeon and Jung Kook Kim. Their combined expertise contributes to the success of their projects and enhances the innovative capabilities of their team.

Conclusion

Seung Dal Seo's work in developing the microjet drug injection device showcases his commitment to improving medical technology. His contributions are paving the way for safer and more effective drug delivery systems.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…